Teva Pharmaceuticals (NYSE:TEVA) has a new treatment it can market. The company's Actavis Generics unit has been granted Food and Drug Administration (FDA) approval for its Pemetrexed chemotherapy treatment, which combats lung cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,